On February 20, Gilead Sciences announced that the National Medical Products Administration had approved the marketing authorization application for AmBisome® (AmBisome® Liposomal Amphotericin B for Injection, 50mg) for the treatment of invasive fungal diseases.
Gilead Sciences Announces NMPA Approval of AmBisome® (Liposomal Amphotericin B) for Invasive Fungal Diseases in China
Feb 20, 2023 17:57
CST Updated
17:57
Gilead Sciences
Antiviral Drug Developer